This is the logo of the provider
ADA 2025 20 - 23 June 2025

Once-weekly semaglutide versus placebo for the treatment of type 2 diabetes and chronic kidney disease in Denmark: A long-term cost-effectiveness analysis based on FLOW

Authors :

Peter Rossing1,2; Morten Lindhardt2,3; Christian Klyver Tikkanen4; Jyothi Menon5; Juliette Cattin6; Barnaby Hunt6; Samuel JP Malkin6; Barrie Chubb5; Tina Damgaard4; Rikke Borg2,7

Affiliations
View Details Hide Details
Download poster (.pdf)
This is the logo of the provider
{{ getPageNum(PDFPage) }}
Keywords
Diabetes
Chronic Kidney Disease
Congress poster
GLP-1 RA
Semaglutide